This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

IHD (WOSCOPS)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

6595 middle-aged men (age 45-64) with a mean cholesterol of 7.0 +/- 0.6 mmol were randomised to pravastatin 40 mg per day or placebo.

The average follow-up was 4.9 years.

Pravastatin altered serum lipids in the following manner:

  • serum cholesterol was reduced by 20%
  • serum LDL cholesterol was reduced by 26%

The relative risks in the pravastatin group reduced by:

  • 31% for coronary events
  • 31% for non-fatal myocardial infarction
  • 28% for death from definite coronary artery disease
  • reduction in total mortality by 22%

There was no significant excess in non-cardiovascular deaths in the pravastatin group.

Calculated - treating 1000 patients for 5 years - saves 7 deaths from CHD and 20 non-fatal MIs (1)

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the following 10 years (2):

  • in this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.